Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 + Paclitaxel in Advanced Solid Tumors, Breast Cancer, and HNSCC
NCT02051751Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of alpelisib in solid tumor, breast cancer and head and neck squamous cell carcinoma (HNSCC), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicity and Number of patients with adverse events. Started Mar 2014; status: completed.
02
Drugs
alpelisib
03
Conditions
solid tumorbreast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02051751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02051751.